The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis
Articolo
Data di Pubblicazione:
2021
Citazione:
The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis / M. Ferro, F. Del Giudice, G. Carrieri, G.M. Busetto, L. Cormio, R. Hurle, R. Contieri, D. Arcaniolo, A. Sciarra, M. Maggi, F. Porpiglia, M. Manfredi, C. Fiori, A. Antonelli, A. Tafuri, P. Bove, C. Terrone, M. Borghesi, E. Costantini, E. Iliano, E. Montanari, L. Boeri, G.I. Russo, M. Madonia, A. Tedde, A. Veccia, C. Simeone, G. Liguori, C. Trombetta, E. Brunocilla, R. Schiavina, F. Dal Moro, M. Racioppi, M.D. Vartolomei, N. Longo, L. Spirito, F. Crocetto, F. Cantiello, R. Damiano, S.M. Di Stasi, M. Marchioni, L. Schips, P. Parma, L. Carmignani, A. Conti, F. Soria, P. Gontero, B. Barone, F. Deho, E. Zaffuto, R. Papalia, R.M. Scarpa, V. Pagliarulo, G. Lucarelli, P. Ditonno, F.M.G. Botticelli, G. Musi, M. Catellani, O. de Cobelli. - In: CANCERS. - ISSN 2072-6694. - 13:21(2021), pp. 5276.1-5276.17. [10.3390/cancers13215276]
Abstract:
Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). Methods: A retrospective analysis was per-formed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 out-break, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, p = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, p < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups (n = 453, 86% vs. n = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, p < 0.0001). Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Bladder cancer; Intravesical BCG; Re-TURBT; SARS-CoV-2; Trans-urethral resection of bladder tumor
Elenco autori:
M. Ferro, F. Del Giudice, G. Carrieri, G.M. Busetto, L. Cormio, R. Hurle, R. Contieri, D. Arcaniolo, A. Sciarra, M. Maggi, F. Porpiglia, M. Manfredi, C. Fiori, A. Antonelli, A. Tafuri, P. Bove, C. Terrone, M. Borghesi, E. Costantini, E. Iliano, E. Montanari, L. Boeri, G.I. Russo, M. Madonia, A. Tedde, A. Veccia, C. Simeone, G. Liguori, C. Trombetta, E. Brunocilla, R. Schiavina, F. Dal Moro, M. Racioppi, M.D. Vartolomei, N. Longo, L. Spirito, F. Crocetto, F. Cantiello, R. Damiano, S.M. Di Stasi, M. Marchioni, L. Schips, P. Parma, L. Carmignani, A. Conti, F. Soria, P. Gontero, B. Barone, F. Deho, E. Zaffuto, R. Papalia, R.M. Scarpa, V. Pagliarulo, G. Lucarelli, P. Ditonno, F.M.G. Botticelli, G. Musi, M. Catellani, O. de Cobelli
Link alla scheda completa: